Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adicet BioFRA:1IJ +3.47%35 PB Ratio is 0.59 as of Jul. 28, 2026, which is 64% above its 10-year median of 0.36. GuruFocus rates FRA:1IJ with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 1,228 Biotechnology companies, Adicet Bio ranks better than 93.08% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-28), Adicet Bio's share price is €7.45. Adicet Bio's Book Value per Share for the quarter that ended in Mar. 2026 was €12.62. Hence, Adicet Bio's PB Ratio of today is 0.59.
Warning Sign:
Adicet Bio Inc stock PB Ratio (=0.56) is close to 3-year high of 0.56.
The historical rank and industry rank for Adicet Bio's PB Ratio or its related term are showing as below:
FRA:1IJ'
s PB Ratio Range Over the Past 10 Years
Min: 0.06 Med: 0.36 Max: 3.01
Current: 0.56
During the past 8 years, Adicet Bio's highest PB Ratio was 3.01. The lowest was 0.06. And the median was 0.36.
FRA:1IJ's PB Ratio is ranked better than 93.08% of 1228
companies
in the Biotechnology industry
Industry Median: 2.78
vs FRA:1IJ: 0.56
During the past 12 months, Adicet Bio's average Book Value Per Share Growth Rate was -53.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -46.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -30.30% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Adicet Bio was -11.00% per year. The lowest was -46.60% per year. And the median was -33.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Adicet Bio PB Ratio Related Terms
Adicet Bio PB Ratio Historical Data
* Premium members only.
The historical data trend for Adicet Bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adicet Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Adicet Bio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Adicet Bio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Adicet Bio (FRA:1IJ) has a PB Ratio of 0.59 as of Jul. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Adicet Bio and its competitors. This is 64% above median its historical median of 0.36. Over the past decade, Adicet Bio's PB Ratio has ranged from 0.06 to 3.01. According to the industry distribution chart, Adicet Bio ranks #85 out of 1228 companies in the Biotechnology industry, placing it in the top 6.9%.
Is Adicet Bio's PB Ratio too high?
Adicet Bio's current PB Ratio of 0.59 is 64% above median its 10-year median of 0.36. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 3.01. The Biotechnology industry median PB Ratio is 2.78. Adicet Bio's value of 0.59 is 78.8% below this industry median. Based on the distribution chart, Adicet Bio ranks #85 out of 1228 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Adicet Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's PB Ratio compare to ATRA and PYPD?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #85 out of 1228 companies for PB Ratio. This places Adicet Bio in the top 7% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.78. Adicet Bio's value of 0.59 is 78.8% below this benchmark. Historically, Adicet Bio's own PB Ratio has ranged from 0.06 to 3.01 over the past decade. While the company's 10-year median is 0.36 vs. the industry median of 2.78, Adicet Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.78, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adicet Bio's current PB Ratio of 0.59 is 78.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Adicet Bio and its competitors. For the Biotechnology industry, the median PB Ratio is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adicet Bio's current PB Ratio is 0.59, which is 64% above median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (FRA:1IJ) has a current PB Ratio of 0.59. The current PB Ratio is 0.59, which is 64% above median its 10-year median of 0.36 and 78.8% below the Biotechnology industry median of 2.78. Adicet Bio's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Adicet Bio (FRA:1IJ), the current PB Ratio is 0.59 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
35GF Score
Get the complete analysis for FRA:1IJ
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1IJ has been successfully added to your 
